GU Cancers Symp. 2014: Testicular Cancer

REVIEW UroToday

Viewing 1-7 of 7 articles

GU Cancers Symposium 2014 - Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor - Session Highlights

GU Cancers Symposium 2014 - Is high-dose chemotherapy plus stem-cell transplant the standard treatment for patients for whom first-line chemotherapy for metastatic germ cell tumor failed? - Session Highlights

GU Cancers Symposium 2014 - Is early-chemotherapy switch the standard treatment for poor-risk metastatic disease and slow tumor marker decline? - Session Highlights

GU Cancers Symposium 2014 - Is surveillance the standard treatment for clinical stage I germ cell tumor? - Session Highlights

GU Cancers Symposium 2014 - A decade in review: Penile, urethral, and testicular cancers - Session Highlights

GU Cancers Symposium 2014 - Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression - Session Highlights

GU Cancers Symposium 2014 - Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin for patients with refractory germ cell tumors including late relapse - Session Highlights